Cytokine Release Syndrome with Relative Adrenal Insufficiency Induced by Ipilimumab and Nivolumab Combination Therapy for Clear Cell Renal Cell Carcinoma
Combination therapy with ipilimumab and nivolumab is indicated for many types of cancers; however, several patients experience immune-related adverse events (irAEs). We herein report a case of cytokine release syndrome (CRS) in a 63-year-old woman with stage IV left clear cell renal cell carcinoma. Our patient developed CRS while taking prednisolone, 43 days after the start of ipilimumab and nivolumab administration. The patient was treated with steroid pulse therapy, which improved the symptoms of shock and respiratory failure. Increased vascular permeability and relative adrenal insufficiency are considered to be the main pathogeneses. The early administration of high-dose steroids is crucial as a replacement for corticosteroids.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Internal medicine (Tokyo, Japan) - (2024) vom: 04. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamamoto, Kohei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal insufficiency |
|---|
| Anmerkungen: |
Date Revised 03.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2169/internalmedicine.3115-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369228324 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369228324 | ||
| 003 | DE-627 | ||
| 005 | 20240304233148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2169/internalmedicine.3115-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM369228324 | ||
| 035 | |a (NLM)38432959 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamamoto, Kohei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytokine Release Syndrome with Relative Adrenal Insufficiency Induced by Ipilimumab and Nivolumab Combination Therapy for Clear Cell Renal Cell Carcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Combination therapy with ipilimumab and nivolumab is indicated for many types of cancers; however, several patients experience immune-related adverse events (irAEs). We herein report a case of cytokine release syndrome (CRS) in a 63-year-old woman with stage IV left clear cell renal cell carcinoma. Our patient developed CRS while taking prednisolone, 43 days after the start of ipilimumab and nivolumab administration. The patient was treated with steroid pulse therapy, which improved the symptoms of shock and respiratory failure. Increased vascular permeability and relative adrenal insufficiency are considered to be the main pathogeneses. The early administration of high-dose steroids is crucial as a replacement for corticosteroids | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adrenal insufficiency | |
| 650 | 4 | |a cytokine release syndrome | |
| 650 | 4 | |a immune-related adverse event | |
| 650 | 4 | |a ipilimumab | |
| 650 | 4 | |a nivolumab | |
| 700 | 1 | |a Shiotsu, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Sasakura, Misaki |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Shunya |e verfasserin |4 aut | |
| 700 | 1 | |a Goda, Shiho |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuji, Taisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yuba, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Takumi, Chieko |e verfasserin |4 aut | |
| 700 | 1 | |a Hiraoka, Noriya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine (Tokyo, Japan) |d 1996 |g (2024) vom: 04. März |w (DE-627)NLM012606731 |x 1349-7235 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:04 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2169/internalmedicine.3115-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 04 |c 03 | ||